FGH BioTech Overview
- Founded
- 2011
- Status
- Private
- Latest Deal Type
- Later Stage VC
- Latest Deal Amount
- $2.08M
- Investors
- 2
FGH BioTech General Information
Description
Developer of small molecule drugs designed to treat metabolic disorders and cancer. The company's drugs target the master regulatory switch for fat production, known as sterol regulatory element-binding proteins (SREBP), enabling physicians to treat obesity, non-alcoholic fatty liver disease, type II diabetes, and lipid disorders.
Contact Information
Website
www.fghbiotech.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 414 Thamer Circle
- Houston, TX 77024
- United States
+1 (713) 000-0000
FGH BioTech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 19-May-2018 | $2.08M | 00.000 | Completed | Generating Revenue | |
| 3. Early Stage VC (Series A) | 18-Mar-2016 | 000 | 000 | 0000 | Completed | Generating Revenue |
| 2. Angel (individual) | 06-Nov-2015 | Cancelled | Generating Revenue | |||
| 1. Grant | 01-Jan-2014 | $1.84M | Completed | Generating Revenue |
FGH BioTech Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 000,000 | 00.000000 | 000 | 000 | 00 | 000 | 00.000 |
FGH BioTech Patents
FGH BioTech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3510027-A1 | Di-substituted pyrazole compounds for the treatment of diseases | Pending | 07-Sep-2016 | 0000000000 | |
| JP-2019530742-A | Disubstituted pyrazole compounds for the treatment of diseases | Pending | 07-Sep-2016 | 0000000000 | |
| AU-2017323521-A1 | Di-substituted pyrazole compounds for the treatment of diseases | Granted | 07-Sep-2016 | 0000000000 | |
| US-20190194167-A1 | Di-substituted pyrazole compounds for the treatment of diseases | Pending | 07-Sep-2016 | 0000000000 | 0 |
| CA-3036195-A1 | Di-substituted pyrazole compounds for the treatment of diseases | Pending | 07-Sep-2016 | C07D401/14 |
FGH BioTech Executive Team (4)
FGH BioTech Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| Adam Kuspa | FGH BioTech | Board Member | 000 0000 |
| Joe Wakil | FGH BioTech | President & Board Member | 000 0000 |
| Salih Wakil Ph.D | FGH BioTech | Co-Founder, President & Chairman | 000 0000 |
FGH BioTech Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| BCM Technologies | Venture Capital | Minority | 000 0000 | 000000 0 | |
| U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 |